NCT01299636 - Study of PM060184 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Solid Tumors

Interventions

DRUG

PM060184

PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.

Trial Locations (1)

78229

START- South Texas Accelerated Research Therapeutics, LLC, San Antonio